2. Signaling Pathways
  3. Apoptosis
  4. Ferroptosis

Ferroptosis

Ferroptosis

Ferroptosis

Related Products

PDF 0.68 MB

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156286
    GPX4-IN-7
    		Inducer
    GPX4-IN-7 (Compound 31), indirubin derivative, is a ferroptosis inducer for colon cancer. GPX4-IN-7 has strong antitumor activity against HCT-116 cells with an IC50 value of 0.49 μM. GPX4-IN-7 can promote the degradation of GPX4, causing the accumulation of lipid ROS to induce ferroptosis.
    GPX4-IN-7
  • HY-N11885
    Ferroptosis-IN-1
    		Inhibitor
    Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits ferroptosis with an EC50 value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research.
    Ferroptosis-IN-1
  • HY-170675
    Ferroptosis-IN-13
    		Inhibitor
    Ferroptosis-IN-13 (compound NY-26) is a ferroptosis inhibitor. Ferroptosis-IN-13 inhibits RSL3(HY-100218A)-induced ferroptosis in 786-O cells with an EC50 value of 62 nM.
    Ferroptosis-IN-13
  • HY-N0504S1
    Lovastatin-d9
    		Activator 99.04%
    Lovastatin-d9 is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
    Lovastatin-d<sub>9</sub>
  • HY-N0193S
    Artesunate-d3
    		Activator
    Artesunate-d3 is the deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
    Artesunate-d<sub>3</sub>
  • HY-168118
    Ferroptosis-IN-14
    		Inhibitor
    Ferroptosis-IN-14 (compund 36) exhibits the potent anti-ferroptosis activity with an EC50 value of 0.58 ± 0.02 μM and possessed excellent anti-ferroptosis activity, microsomal and plasma stability.
    Ferroptosis-IN-14
  • HY-B0165AS
    Pravastatin-13C,d3 sodium
    		Activator
    Pravastatin-13C,d3 (sodium) is the 13C- and deuterium labeled Pravastatin (sodium). Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin-<sup>13</sup>C,d<sub>3</sub> sodium
  • HY-161760
    Ferroptosis inducer-3
    		Inhibitor
    Ferroptosis inducer-3 (compound JB3) is an oral bioactive inhibitor of RAF1, with the IC50 of 226.9 nM. Ferroptosis inducer-3 can induce ferroptosis and plays an important role in cancer research.
    Ferroptosis inducer-3
  • HY-170509
    Ferroptosis-IN-17
    		Inhibitor
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases.
    Ferroptosis-IN-17
  • HY-175000
    L14-8
    		Inducer
    L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer.
    L14-8
  • HY-162311
    Anticancer agent 194
    		Inhibitor
    Anticancer agent 194 (compound 10p) is a ferroptosis and autophagy inducer. Anticancer agent 194 arrests colon cancer cell cycle at G2/M phase, but can't induce cell apoptosis. Anticancer agent 194 independently triggeres cell ferroptosis and autophagy through the massive accumulation of ROS.
    Anticancer agent 194
  • HY-P10852
    TAT-MKK3b
    		Inhibitor
    TAT-MKK3b is a p38 peptide inhibitor. TAT-MKK3b can inhibit p38 phosphorylation. TAT-MKK3b has renal targeting, ROS-scavenging, and ferroptosis-mitigating capabilities. TAT-MKK3b improves acute kidney injury and its progression to chronic kidney disease.
    TAT-MKK3b
  • HY-N0504S2
    Lovastatin-d3
    		Activator
    Lovastatin-d3 is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
    Lovastatin-d<sub>3</sub>
  • HY-169287
    TriPEX-ClO4
    		Inhibitor
    TriPEX-ClO4 is a cationic fluorescent anticancer agent capable of BBB penetration. TriPEX-ClO4 can induces apoptosis and ferroptosis and can be used for study of cancer and brain diseases.
    TriPEX-ClO4
  • HY-N0193S1
    Artesunate-d4
    		Activator
    Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).
    Artesunate-d<sub>4</sub>
  • HY-168261
    CQ-ER
    		Inducer
    CQ-ER is a Coumarin (HY-N0709)-Quinazolinone based endoplasmic reticulum (ER)-targeted photosensitizer. CQ-ER can cause ferroptosis, thereby enhancing photodynamic therapy (PDT).
    CQ-ER
  • HY-161668
    Ru-Poma
    		Inducer
    Ru-Poma is a Ru(II)-based photosensitizer, which attenuates Cisplatin (HY-17394)-resistant tumor through photodynamic therapy (PDT). Ru-Poma photodegrades CRBN through a Pomalidomide (HY-10984) moiety. Ru-Poma induces ferroptosis, through an increase in lipid peroxide, downregulation of GPX4 and GAPDH expression. Ru-Poma exhibits cytotoxicity in A549, with IC50 of 18.46 μM and 0.37 μM in dark and upon irradiation, respectively.
    Ru-Poma
  • HY-17359S
    Deferasirox-d4
    		Inhibitor
    Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.
    Deferasirox-d<sub>4</sub>
  • HY-14291S2
    Vildagliptin-13C5,15N
    		Inhibitor
    Vildagliptin-13C5,15N (LAF237-13C5,15N; NVP-LAF 237-13C5,15N) is a 13C- and 15N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
    Vildagliptin-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N
  • HY-50898S1
    Lapatinib-d7 dihydrochloride
    		Activator
    Lapatinib-d7 dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib-d<sub>7</sub> dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity
All Rights Reserved.
Download Ferroptosis Signaling Pathway Map.